Skip to NavigationSkip to content

COVID-19

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on Friday suggest that protection from their respective COVID-19 vaccines wanes over time. This comes as the FDA consider the approval of a booster programme in the US.

Moderna shared new data about its vaccine on Wednesday. In addition to the jab being highly effective against new strains, the company released data from their Phase III COVE study suggesting that a booster dose of the vaccine will support greater efficacy for the population.

Sanofi complete acquisition of mRNA company Translate Bio

Freepik | tirachardz

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal for Translate Bio, a Massachusetts-based company specialising in mRNA technology for vaccines.

The acquisition is Sanofi’s fourth of this year and joins Kymab Ltd, Tidal Therapeutics, and Kadmon Corporation in their portfolio additions. The acquisition of Translate Bio comes after Sanofi announced its mRNA centre of excellence in June, where it is investing €400 million each year in producing vaccines using mRNA.

BioNTech seek approval for COVID-19 vaccine in children aged 5-11

Children between 5 and 11 years old are to be targeted by BioNTech as the company seeks approval for younger populations. The FDA have released a statement outlining their need to "follow the science" when approving the jab for children.

With almost 44 million people in the UK double vaccinated, Pfizer-BioNTech have announced that they will be applying for authorisation in paediatric populations.

China rejects a second WHO probe into COVID outbreak origin

China has rejected WHO plans for a second investigation into the origin of the coronavirus pandemic, which includes the hypothesis it could have escaped from a Chinese laboratory.

The WHO has proposed a second phase of studies into the origins of the coronavirus in China, including audits of laboratories and markets in the city of Wuhan, calling for transparency from authorities.

Fears for pregnant women as COVID restrictions ease

The Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM) have expressed fears over the planned easing of COVID restrictions, warning of increased infections among pregnant women.

Studies have found that pregnant women may be at higher risk of becoming severely ill with COVID in the late stage of pregnancy due the pressure exerted on the lungs by the growing foetus.

The RCOG and RCM have publicly urged pregnant women to get vaccinated, "to protect yourself, your baby and your family".

Lethal triple mix of winter viruses could “push NHS to breaking point”

A report from the Academy of Medical Sciences has found that a lethal triple mix of COVID-19, influenza, and the respiratory virus Respiratory Syncytial Virus (RSV), could push an already depleted NHS to breaking point this winter.

The report brought together 29 leading experts alongside 57 members of the public, at the request of the Government Chief Scientific Adviser, to forecast the greatest risks to health this winter, finding a number of concerning predictions.

New warning added to J&J vaccine in US

The FDA has made the decision to add a warning to the fact sheet for Johnson & Johnson's COVID-19 vaccine, as data suggests there is an increased risk of a rare neurological disorder, Guillain-Barré syndrome (GBS), in the six weeks after inoculation.

In a letter to J&J the FDA did acknowledge that the chances of contracting GBS were “very low” but that individuals should seek medical attention if they show any of the following symptoms: weakness or tingling sensations, difficulty walking, or difficulty with facial movements.

Spanner in the works for Sputnik V as missing data reported

Photo by Gustavo Fring from Pexels

Developers of Russia’s Sputnik V COVID-19 vaccine have repeatedly failed to present data to regulators, Reuters has reported.

Five sources with knowledge of European efforts to assess the drug have informed Reuters that standard data required for the approval process has repeatedly been missed by the drug’s developers.

Reuters reported last month that the EMA’s review of the drug’s safety and efficacy was delayed because a June 10 deadline to submit data on the vaccine's clinical trials was missed, however the issue of missed data goes further than this.

Children “extremely low risk” from COVID study finds

Photo by Ketut Subiyanto from Pexels

The overall risk of children becoming severely ill or dying from COVID-19 is extremely low, scientists from University College London, and the Universities of York, Bristol, and Liverpool have confirmed in a study.

Data from the first 12 months of the pandemic has shown only 25 people under the age of 18 died from COVID-19, which puts the overall risk of death at around two in a million for children, researchers have estimated.

Summer COVID cases set to reach 2 million with 10 million isolating

Analysis from the Guardian has found that over two million people could contract COVID-19 this summer, which could therefore lead to over 10 million people being forced to self-isolate.

These figures have been estimated from data modelling presented to MPs, which suggested infections could reach 50,000 a day by July 19 and then 100,000 a day later in the summer.

100,000 daily infections is still an unprecedented figure in the UK, with the highest figure reported so far reaching 81,000 in December last year.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches